Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01954524 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01954524 is a Phase 1 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 2 participants.
The verdict
NCT01954524, a Phase 1 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Safety and tolerability of a single dose intravenous bolus injection of Sildenafil in patients with moderate to severe cirrhosis and kidney disease will be determined.
Interventions
- DRUG IV bolus injection of Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01954524
The ClinicalTrials.gov registry entry for NCT01954524 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IV bolus injection of Sildenafil is the first listed.
NCT01954524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01954524 about?
NCT01954524 is a clinical study titled "A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis". Safety and tolerability of a single dose intravenous bolus injection of Sildenafil in patients with moderate to severe cirrhosis and kidney disease will be determined.
What is the current status of trial NCT01954524?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01954524?
The interventions under investigation include: IV bolus injection of Sildenafil (DRUG).
Who is sponsoring clinical trial NCT01954524?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.